分析糖皮质激素联合特布他林治疗慢阻肺急性加重期的临床价值

目的:探讨糖皮质激素联合特布他林对慢性阻塞性肺疾病(慢阻肺)急性加重期患者的疗效。方法:选取我院自2018年1月—2019年7月慢阻肺急性加重期患者200例为观察对象,按照随机数表法分为对照组和观察组,各100例。两组均给予常规对症治疗,对照组在此基础上给予特布他林雾化吸入治疗,观察组在对照组基础上给予糖皮质激素普米克令舒雾化吸入治疗,对比两组疗效、血清炎症因子、肺功能。结果:观察组总有效率为98.00%(98/100),高于对照组的90.00%(90/100)(P<0.05);治疗后两组IL-8、TNF-α均下降,其中观察组低于对照组(P<0.05);治疗后两组FEV1、FVC、PEF升高,其中观察组高于对照组(P<0.05)。结论:糖皮质激素联合特布他林能够减轻慢阻肺急性加重期患者的机体炎症反应,改善肺功能,提高疗效,具有较高应用价值。

Clinical value of glucocorticoid combined with terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective:To investigate the effect of glucocorticoid combined with terbutaline on acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:200 patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital from January 2018 to July 2019 were selected as the observation objects.According to the random number table method,they were divided into control group and observation group,100 cases in each group.Both groups were given symptomatic support treatment routinely.On this basis,the control group was given aerosol inhalation of terbutaline,while the observation group was given aerosol inhalation of terbutaline on the basis of the control group.Glucocorticoid Pulmicort reshuffle aerosol inhalation therapy was given.The efficacy,serum inflammatory factors and lung function of the two groups were compared.Results:The total effective rate of the observation group was 98.00%(98/100),higher than 90.00%(90/100)of the control group(P<0.05).After treatment,the levels of IL-8 and TNF-alpha in the two groups decreased,and the levels of FEV1,FVC and PEF in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of FEV1,FVC and PEF in the two groups increased,and the observation group was higher than that in the control group Conclusion:Glucocorticoid combined with terbutaline can alleviate inflammation,improve pulmonary function and improve curative effect in patients with acute exacerbation of chronic obstructive pulmonary disease.